AVROBIO, Inc. Profile Avatar - Palmy Investing

AVROBIO, Inc.

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modif…

Biotechnology
US, Cambridge [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

AVROBIO, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of AVRO's Analysis
CIK: 1681087 CUSIP: 05455M100 ISIN: US05455M1009 LEI: - UEI: -
Secondary Listings
AVRO has no secondary listings inside our databases.